SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that multiple posters for the Prosigna® Breast Cancer Gene Signature Assay based on PAM50 will be presented at the 37th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS). These include a prospective study of the Prosigna Assay on adjuvant clinical decision-making in women with Estrogen Receptor-Positive (ER+), HER2-negative, node-negative breast cancer. This decision impact study, performed in conjunction with Grupo Español de Investigación del Cáncer de Mama (GEICAM), a Spanish breast cancer research group, is the first of its kind to provide insights into the changes in clinical practice derived from the use of the Prosigna Assay.
Help employers find you! Check out all the jobs and post your resume.
